EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Treatment reduces the incidence of newly appearing multiple sclerosis lesions evolving into chronic active, slowly expanding lesions: A retrospective analysis

Alberto Calvi iD, Zoe Mendelsohn, Weaam Hamed, Declan Chard, Carmen Tur, Jon Stutters iD, David MacManus, Baris Kanber, Claudia A M Gandini Wheeler-Kingshott, Frederik Barkhof, Ferran Prados

European Journal of Neurology · 2024-01 · 31 (1)

DOI: 10.1111/ene.16092 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Neurology, online erschienen am 12.10.2023. Verfasst von Alberto Calvi und 10 weiteren Autor:innen. Beteiligte Einrichtung: NMR Research Unit, Institute of Neurology, University College London, London, UK. Hauptthemen laut MEDLINE: Multiple Sclerosis, Multiple Sclerosis, Chronic Progressive. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Multiple Sclerosis Society, European Committee for Treatment and Research in Multiple Sclerosis, International Progressive MS Alliance.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and purpose Newly appearing lesions in multiple sclerosis (MS) may evolve into chronically active, slowly expanding lesions (SELs), leading to sustained disability progression. The aim of this study was to evaluate the incidence of newly appearing lesions developing into SELs, and their correlation to clinical evolution and treatment.

Methods

A retrospective analysis of a fingolimod trial in primary progressive MS (PPMS; INFORMS, NCT 00731692) was undertaken. Data were available from 324 patients with magnetic resonance imaging scans up to 3 years after screening. New lesions at year 1 were identified with convolutional neural networks, and SELs obtained through a deformation‐based method. Clinical disability was assessed annually by Expanded Disability Status Scale (EDSS), Nine‐Hole Peg Test, Timed 25‐Foot Walk, and Paced Auditory Serial Addition Test. Linear, logistic, and mixed‐effect models were used to assess the relationship between the Jacobian expansion in new lesions and SELs, disability scores, and treatment status.

Results

One hundred seventy patients had ≥1 new lesions at year 1 and had a higher lesion count at screening compared to patients with no new lesions (median = 27 vs. 22, p = 0.007). Among the new lesions (median = 2 per patient), 37% evolved into definite or possible SELs. Higher SEL volume and count were associated with EDSS worsening and confirmed disability progression. Treated patients had lower volume and count of definite SELs ( β = −0.04, 95% confidence interval [CI] = −0.07 to −0.01, p = 0.015; β = −0.36, 95% CI = −0.67 to −0.06, p = 0.019, respectively).

Conclusions

Incident chronic active lesions are common in PPMS, and fingolimod treatment can reduce their number.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple SclerosisMultiple Sclerosis, Chronic ProgressiveHumansFingolimod HydrochlorideRetrospective StudiesIncidenceMagnetic Resonance Imaging

Stichwörter der Autor:innen

chronic active lesionsfingolimodprimary progressive multiple sclerosisslowly expanding lesions (SELs)volumetric MRI

Substanzen

Fingolimod Hydrochloride

Autor:innen und Institutionen

  • NMR Research Unit, Institute of Neurology, University College London, London, UK.
  • Laboratory of Advanced Imaging in Neuroimmunological Diseases, Hospital Clinic Barcelona, Fundació Clinic per a la Recerca Biomèdica, Barcelona, Spain.
  • Department of Radiology, Charité School of Medicine and University Hospital Berlin, Berlin, Germany.
  • Department of Radiology, Mansoura University Hospital, Mansoura, Egypt.
  • National Institute for Health Research, Biomedical Research Centre, University College London Hospitals, London, UK.
  • Neurology-Neuroimmunology Department, Multiple Sclerosis Centre of Catalonia, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.

ORCID-Profile: Alberto Calvi, Jon Stutters

Förderung

  • Multiple Sclerosis Society
  • European Committee for Treatment and Research in Multiple Sclerosis
  • International Progressive MS Alliance

Zitieren

APA

Calvi, A., Mendelsohn, Z., Hamed, W., Chard, D., Tur, C., Stutters, J., MacManus, D., Kanber, B., Wheeler-Kingshott, C. A. M. G., Barkhof, F., & Prados, F. (2024). Treatment reduces the incidence of newly appearing multiple sclerosis lesions evolving into chronic active, slowly expanding lesions: A retrospective analysis. European Journal of Neurology, 31(1). https://doi.org/10.1111/ene.16092

Vancouver

Calvi A, Mendelsohn Z, Hamed W, Chard D, Tur C, Stutters J, et al. Treatment reduces the incidence of newly appearing multiple sclerosis lesions evolving into chronic active, slowly expanding lesions: A retrospective analysis. European Journal of Neurology. 2024;31(1). doi:10.1111/ene.16092

BibTeX
@article{Calvi2024,
  author = {Calvi, Alberto and Mendelsohn, Zoe and Hamed, Weaam and Chard, Declan and Tur, Carmen and Stutters, Jon and MacManus, David and Kanber, Baris and Wheeler-Kingshott, Claudia A M Gandini and Barkhof, Frederik and Prados, Ferran},
  title = {Treatment reduces the incidence of newly appearing multiple sclerosis lesions evolving into chronic active, slowly expanding lesions: A retrospective analysis},
  journal = {European Journal of Neurology},
  year = {2024},
  volume = {31},
  number = {1},
  doi = {10.1111/ene.16092}
}
Kostenlos starten →